secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001683168-26-001609
Event type: other
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma hires Aegis Capital as warrant solicitation agent for 3 months, 10% fee on proceeds
--------------------------------------------------------------------------------

- Engaged Aegis Capital on March 6, 2026 to induce exercise of outstanding warrants on best-efforts basis.
- Term of engagement agreement is three months; Aegis receives 10% of gross proceeds from warrant exercises.
- Company agreed to reimburse Aegis up to $100,000 for legal fees and expenses.
- Engagement includes exclusivity provision: Company cannot solicit other financing during term except existing debt holders.
- Warrants trade under ticker SBFMW on Nasdaq; proceeds would provide non-dilutive capital to the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316826001609/0001683168-26-001609-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316826001609/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-001609

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer